Latest Shareholder Confidence News

Spenda Limited has reshaped its business with significant cost cuts, divested non-core assets, and secured major shareholder backing, positioning itself for cash flow positive operations.

The Takeovers Panel has received an application alleging undisclosed associations and possible breaches of takeover laws following a massive off-market transfer of Adslot shares valued at $723,870.

ClearVue Technologies has exceeded its $1 million target in a Share Purchase Plan, raising $1.29 million and issuing over 14.6 million shares with free attaching options pending shareholder approval.

INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.

SDI Limited shareholders voted overwhelmingly in favour of a $1.40 per share acquisition scheme by InnoXvest Dental, setting the stage for court approval and delisting.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Qube Holdings has postponed its second court hearing for the $5.20-per-share takeover by Rubik Australia, awaiting key regulatory approvals. The company plans to proceed with shareholder meetings and intends to pay a fully franked special dividend if the scheme proceeds.

dorsaVi has raised $500,000 through the exercise of 25 million unlisted options by key shareholders, reinforcing confidence in its advanced AI and neuromorphic semiconductor projects. The capital will accelerate development of its 22nm node technology targeting medical and industrial robotics markets.

Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.

Spenda Limited has secured $1.85 million from its institutional entitlement offer at $0.004 per share, progressing its $8.545 million capital raise aimed at debt reduction and product development. The retail component opens next week to raise an additional $6.7 million.

ImpediMed has successfully closed an oversubscribed Share Purchase Plan, raising $2.1 million following a $13.2 million institutional placement. The strong shareholder response underscores confidence ahead of a key shareholder vote.

Paradigm Biopharmaceuticals has successfully raised $21.375 million through an oversubscribed Share Purchase Plan and a recent placement, bolstering its balance sheet ahead of key Phase 3 trial milestones.